A randomized, double-blind, controlled study of AKL-T02 (which retains the same SSME therapeutic engine as AKL-T01) in 19 children ages 9-13 years old with ASD and comorbid ADHD, 11 randomized to AKL-T02 and 8 to digital control. AKL-T02 group improved in TOVA API (mean change=1.86, p=0.12, d=0.72) while the Control group worsened (mean change= -0.82, p=0.55, d=0.35). AKL-T02 group improved in ADHD symptoms (ADHD-RS-Total, mean change= -6.72, p=0.003, d=2.03). Both groups had high compliance with their intervention. There was one non-serious adverse event (decreased frustration tolerance) in the AKL-T02 group.

Sit tight, a representative from Akili Assist® will reach out to you soon.

How do I find my version number?

Sit tight, a representative from
Akili Assist^® will reach out to you soon.